Contact: Jennifer Gutierrez
Department of Genetics and Genomic Sciences 

Mount Sinai accelerates data-driven discovery and patient care with new Chief Data Officer role

Newswise — (New York, NY — May 29, 2019) — Andrew Kasarskis, PhD, an internationally recognized expert in biomedical data, has been named Executive Vice President and Chief Data Officer (CDO) of the Mount Sinai Health System. In this new role, Dr. Kasarskis will facilitate the accessibility and sharing of clinical, financial, and administrative data, and open application development, all in support of better patient care, decision-making, and healthcare innovation.

“The addition of this role at Mount Sinai provides an exceptional opportunity to strengthen our healthcare system’s overall data literacy and culture,” Dr. Kasarskis says. “I want everyone here to view the vast data available to us as an asset we can use objectively to improve efficiency and quality of care, identify patient cohorts for groundbreaking research, enhance the education we provide trainees through the Icahn School of Medicine at Mount Sinai, and add value to all of our organizational efforts.”

The creation of this position builds on Mount Sinai’s reputation as one of the most innovative healthcare and research organizations in the country by putting data front and center in its organizational efforts to better patient care. Named one of Fast Company’s most innovative companies in Data Science and Big Data in 2014 and 2016 and one of “Health Care’s Most Wired” organizations from the American Hospital Association’s (AHA) Health Forum in 2015, 2016, and 2017, Mount Sinai is recognized as a leader in data science capabilities and applications. In addition to Mount Sinai’s rich expertise and industry leadership in data science, its large, diverse patient population, robust research programs, and history of launching data-intensive businesses provides the healthcare system a unique opportunity in this space.

Mount Sinai is among the first large healthcare systems to explicitly define this role to advance patient outcomes, innovation, and research. Dr. Kasarskis will take the lead in driving simplification, transparency, and use of Mount Sinai’s digital assets, supporting entrepreneurial activities at the Icahn School of Medicine at Mount Sinai, and adopting key performance metrics to determine both the impact of infrastructure improvements and the success of each data-driven project going forward.

“By building a data-driven environment where we can assess hospital initiatives for impact, we can achieve a much faster loop to identify treatment-related issues and opportunities, access the necessary data to address them, conceptualize interventions that have the potential to deliver positive patient outcomes, and realize the benefits more quickly and to a much greater extent than was previously possible,” said Dr. Kasarskis.

In meeting the objectives of this new role, Dr. Kasarskis will work closely with Kenneth L. Davis, MD, the President and Chief Executive Officer of the Mount Sinai Health System and Kumar Chatani, Executive Vice President and Chief Information Officer at Mount Sinai, who will lead the implementation of the necessary infrastructure to enable system-wide data sharing through standards based data architecture and interoperability that enables Mount Sinai and partners to deliver value across disparate technology and infrastructure.

“The CDO position will play a crucial role in continuously advancing Mount Sinai’s capabilities for our patients and the entire healthcare system. We knew we needed a leader with deep expertise in the development of medical and research technologies that can harness information and deliver invaluable insights into the genetics and pathology of diseases, which is a rare combination of expertise to find,” Dr. Davis says.  “We are excited about Dr. Kasarskis’s vision to encourage more data-driven commercial partnerships, spinoffs, and patient initiatives to address healthcare needs.”

Dr. Kasarskis has more than two decades of expertise in managing research and technology development projects in software engineering, drug development, human and mouse genetics, and other biological research applications. Prior to joining Mount Sinai, he developed genome databases at Stanford University, participated in the launch of Sage Bionetworks, a not-for-profit medical research organization that advances human health through by making science more open, collaborative, and inclusive, and held senior positions with Pacific Biosciences, Rosetta Inpharmatics, and Merck. 

Prior to this appointment, Dr. Kasarskis served as Director of the Icahn Institute for Genomics and Multiscale Biology at the Icahn School of Medicine. He has stepped down from those roles but will retain his role as a Professor in the Department of Genetics and Genomic Sciences. He will also continue to conduct research in the development and application of technology in areas such as pathogen surveillance, pharmacogenomics, viral infections, and chronic disease.

Dr. Kasarskis earned his PhD in Molecular and Cellular Biology from UC Berkeley as well as a BS in Biology and a BA in Chemistry from the University of Kentucky.

About the Mount Sinai Health System

The Mount Sinai Health System is New York City's largest integrated delivery system, encompassing eight hospitals, a leading medical school, and a vast network of ambulatory practices throughout the greater New York region. Mount Sinai's vision is to produce the safest care, the highest quality, the highest satisfaction, the best access and the best value of any health system in the nation. The Health System includes approximately 7,480 primary and specialty care physicians; 11 joint-venture ambulatory surgery centers; more than 410 ambulatory practices throughout the five boroughs of New York City, Westchester, Long Island, and Florida; and 31 affiliated community health centers. The Icahn School of Medicine is one of three medical schools that have earned distinction by multiple indicators: ranked in the top 20 by U.S. News & World Report's "Best Medical Schools", aligned with a U.S. News & World Report's "Honor Roll" Hospital, No. 12 in the nation for National Institutes of Health funding, and among the top 10 most innovative research institutions as ranked by the journal Nature in its Nature Innovation Index. This reflects a special level of excellence in education, clinical practice, and research. The Mount Sinai Hospital is ranked No. 18 on U.S. News & World Report's "Honor Roll" of top U.S. hospitals; it is one of the nation's top 20 hospitals in Cardiology/Heart Surgery, Gastroenterology/GI Surgery, Geriatrics, Nephrology, and Neurology/Neurosurgery, and in the top 50 in six other specialties in the 2018-2019 "Best Hospitals" issue. Mount Sinai's Kravis Children's Hospital also is ranked nationally in five out of ten pediatric specialties by U.S. News & World Report. The New York Eye and Ear Infirmary of Mount Sinai is ranked 11th nationally for Ophthalmology and 44th for Ear, Nose, and Throat. Mount Sinai Beth Israel, Mount Sinai St. Luke's, Mount Sinai West, and South Nassau Communities Hospital are ranked regionally.

For more information, visit or find Mount Sinai on Facebook, Twitter and YouTube.